Vadodara-headquartered Sudeep Pharma has initiated steps toward entering India’s capital markets, filing its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). The proposed initial public offering (IPO) will consist of a fresh issue worth ₹95 crore alongside an offer for sale (OFS) of over 1 crore shares by the promoter group. Aimed at bolstering its production capabilities and funding corporate expansion, the IPO marks a pivotal chapter for the specialty ingredient manufacturer, which serves a global clientele in the pharmaceutical, food, and nutrition sectors.
IPO Structure: Fresh Capital and Promoter Exit
According to the DRHP, the IPO will be structured as a combination of fresh equity issuance and an offer for sale. While the fresh issue is expected to raise ₹95 crore, a concurrent OFS of up to 1,00,76,492 equity shares will be conducted by promoter selling shareholders Sujit Jaysukh Bhayani, Sujeet Jaysukh Bhayani HUF, Shanil Sujit Bhayani, and Avani Sujit Bhayani.
Sudeep Pharma also reserves the right to execute a pre-IPO placement of shares up to ₹19 crore. Should this placement materialize, the size of the fresh issue will be proportionately reduced.
The company has earmarked ₹75.81 crore from the net proceeds of the fresh issue for capital expenditure—specifically, to acquire machinery for expanding its production capacity at the Nandesari facility in Gujarat. The remaining funds will be allocated toward general corporate purposes.
A Legacy in Specialty Ingredients with Global Reach
Founded in 1989, Sudeep Pharma has evolved from a manufacturer of excipients—additives used in drug formulation—to a diversified supplier of more than 100 products across the pharmaceutical, food, and nutrition industries. The company’s strategic focus on high-margin, value-added offerings has enabled it to build a strong position in India’s specialty chemicals and life sciences value chain.
Sudeep operates three manufacturing units in Vadodara, Gujarat, with a cumulative annual capacity of 65,579 metric tonnes as of December 31, 2024. Its facilities serve both domestic and international markets, underpinning the company’s role as a vital link in the global health and nutrition ecosystem.
Strong Customer Relationships and Financial Performance
Sudeep Pharma boasts a robust client portfolio, featuring marquee names such as Pfizer, Intas Pharmaceuticals, Mankind Pharma, Merck Group, Cadila Pharmaceuticals, Micro Labs, and French food giant Danone. These longstanding relationships serve as a testament to the company’s consistent quality standards, supply reliability, and product innovation.
In terms of financials, the company reported revenue from operations of ₹344.45 crore and a profit after tax of ₹94.54 crore for the nine months ending December 31, 2024. These figures highlight a strong operational performance and profitability, making the IPO a potentially attractive proposition for institutional and retail investors alike.
Market Listing and Lead Managers
Post-approval, the equity shares of Sudeep Pharma will be listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). ICICI Securities and IIFL Capital Services have been appointed as the book-running lead managers for the issue, while MUFG Intime India will serve as the registrar.
Given its scale of operations, customer base, and profitability profile, the IPO could generate significant interest from investors seeking exposure to India’s burgeoning pharmaceutical and nutrition supply industries.
Conclusion: Strategic Expansion and Capital Market Debut
With its IPO filing, Sudeep Pharma is entering a new growth phase, one that seeks to balance long-term capital investment with brand and operational scaling. As India’s demand for pharmaceutical and nutraceutical ingredients grows—alongside a push for domestic self-reliance in critical inputs—Sudeep’s listing could position it as a key player in a fast-evolving global supply chain.
The company’s blend of technical expertise, diversified product portfolio, and trusted client relationships offer a compelling story for investors seeking resilience, scalability, and sectoral tailwinds in a post-pandemic economic landscape.
Comments